NHLBI SBIR/STTR Contract Topic

064 Novel Technologies for Assessing Lipoprotein Sub-fractions

(Fast-Track proposals will be accepted.)

Number of anticipated awards: 1-2

Identifying cardiovascular risk factors and understanding the contribution of those risk factors for cardiovascular disease is critical. Identifying individuals at very high risk for CVD and aggressive intervention are a critical factor to minimize the population wide CVD burden. Determining low density lipoprotein (LDL) as well as high density lipoprotein (HDL) particle size distribution may provide additional predictive power to LDL or HDL cholesterol measurement alone to estimate an individual’s risk for CVD. Current systems that can quantify the lipoprotein sub-fractions are labor intensive and need long turnaround time and thus are not practical for routine clinical applications.

Offerors will develop novel technologies for accurate, high throughput measurement of lipoprotein sub-fractions and use the developed technology to study the value of diagnostic performance in CVD.

Phase I proposals should address initial development and feasibility testing of novel lipoprotein sub-fraction measurements.
Phase II proposals should focus on the optimization and standardization of the technology and also compare with existing methods. It is expected that the developed technology be used to study the value of lipoprotein sub- fraction measurements in CVD risk assessment.

For more information, see the FY2012 Contract Solicitation or contact OTAC.

Return to NHLBI contract topics.

Last Updated December 2011